Aadi Bioscience, Inc. is a privately held biopharmaceutical company that specializes in developing and commercializing innovative treatments for diseases driven by the mTOR pathway, a key cellular signaling pathway involved in cell growth and metabolism. The company's flagship product is nab-sirolimus (ABI 009), a formulation of sirolimus bound to albumin nanoparticles designed for injectable suspension. This product is currently being developed for the treatment of advanced malignant PEComa (perivascular epithelioid cell tumor), a rare and aggressive form of cancer.

Aadi Bioscience operates in the biopharmaceutical market, focusing on both rare diseases and conditions with significant unmet medical needs. Their primary clients include healthcare providers, hospitals, and specialty clinics that treat patients with complex and treatment-resistant conditions. The company is also involved in clinical trials aimed at expanding the use of nab-sirolimus for other indications, such as treatment-resistant epilepsy.

The business model of Aadi Bioscience revolves around the development, regulatory approval, and commercialization of their proprietary drug formulations. They generate revenue through the sale of their approved drugs to healthcare institutions and potentially through partnerships or licensing agreements with larger pharmaceutical companies. By focusing on niche markets with high unmet needs, Aadi aims to secure orphan drug designations, which can provide market exclusivity and other financial incentives.

In summary, Aadi Bioscience is a forward-thinking biopharmaceutical company dedicated to bringing new hope to patients with rare and challenging diseases through innovative drug formulations and rigorous clinical research.

Keywords: biopharmaceutical, nab-sirolimus, mTOR pathway, rare diseases, PEComa, epilepsy, drug development, clinical trials, regulatory approval, healthcare providers.